Wells Fargo & Company Issues Positive Forecast for Cencora (NYSE:COR) Stock Price

Cencora logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wells Fargo raised its Cencora price target from $395 to $400 and maintained an Overweight rating, implying about 12% upside from the price cited in the article.
  • Analyst sentiment is broadly positive: 13 analysts rate the stock Buy and three Hold, for a consensus “Moderate Buy” rating and an average target of $376.36.
  • Cencora beat quarterly earnings and revenue expectations, reporting $4.66 EPS and $88.35 billion in revenue; revenue rose 5.5% year over year.
  • Five stocks to consider instead of Cencora.

Cencora (NYSE:COR - Get Free Report) had its price target hoisted by investment analysts at Wells Fargo & Company from $395.00 to $400.00 in a note issued to investors on Tuesday, Benzinga reports. The firm currently has an "overweight" rating on the stock. Wells Fargo & Company's target price points to a potential upside of 12.06% from the company's current price.

A number of other analysts have also issued reports on COR. Wall Street Zen upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. Leerink Partners increased their price target on Cencora from $388.00 to $405.00 and gave the company an "outperform" rating in a research note on Thursday, November 5th. Bank of America boosted their price target on Cencora from $285.00 to $310.00 in a research note on Tuesday, July 21st. UBS Group cut their target price on shares of Cencora from $430.00 to $400.00 and set a "buy" rating for the company in a research report on Friday, October 16th. Finally, JPMorgan Chase & Co. raised their target price on Cencora from $390.00 to $413.00 and gave the company an "overweight" rating in a report on Tuesday, November 10th. Thirteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, Cencora currently has an average rating of "Moderate Buy" and a consensus target price of $376.36.

Check Out Our Latest Stock Report on COR

Cencora Trading Down 0.6%

NYSE:COR opened at $356.96 on Tuesday. The stock has a market capitalization of $68.12 billion, a PE ratio of 19.92, a price-to-earnings-growth ratio of 1.81 and a beta of 0.58. Cencora has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The business's 50-day simple moving average is $327.65 and its 200-day simple moving average is $317.23. The company has a debt-to-equity ratio of 3.01, a current ratio of 0.94 and a quick ratio of 0.59.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $4.66 EPS for the quarter, beating analysts' consensus estimates of $4.58 by $0.08. Cencora had a return on equity of 110.72% and a net margin of 1.03%. The firm had revenue of $88.35 billion for the quarter, compared to analysts' expectations of $87.95 billion. During the same quarter in the prior year, the firm earned $3.84 EPS. The business's revenue for the quarter was up 5.5% compared to the same quarter last year. Sell-side analysts expect that Cencora will post 19.58 earnings per share for the current fiscal year.

Insider Buying and Selling at Cencora

In other news, EVP Elizabeth Campbell sold 11,300 shares of the firm's stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the transaction, the executive vice president directly owned 19,455 shares in the company, valued at approximately $6,305,754.60. This trade represents a 36.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.38% of the company's stock.

Institutional Trading of Cencora

Institutional investors and hedge funds have recently modified their holdings of the business. Lighthouse Investment Partners LLC boosted its holdings in shares of Cencora by 89.9% in the third quarter. Lighthouse Investment Partners LLC now owns 6,753 shares of the company's stock worth $2,028,000 after buying an additional 3,197 shares during the period. WCG Wealth Advisors LLC lifted its holdings in shares of Cencora by 6.1% during the 3rd quarter. WCG Wealth Advisors LLC now owns 33,051 shares of the company's stock valued at $9,924,000 after purchasing an additional 1,892 shares in the last quarter. Worldquant Millennium Advisors LLC lifted its position in shares of Cencora by 820.2% in the third quarter. Worldquant Millennium Advisors LLC now owns 188,526 shares of the company's stock worth $56,605,000 after purchasing an additional 168,039 shares in the last quarter. Keel Point LLC acquired a new stake in shares of Cencora in the third quarter valued at approximately $238,000. Finally, Bellevue Group AG grew its holdings in Cencora by 11.1% in the 3rd quarter. Bellevue Group AG now owns 640 shares of the company's stock valued at $192,000 after buying an additional 64 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Company Profile

(Get Free Report)

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers. The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.

Further Reading

Analyst Recommendations for Cencora (NYSE:COR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cencora Right Now?

Before you consider Cencora, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.

While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines